ENEDYM-INC
10.5.2022 14:02:15 CEST | Business Wire | Press release
Enedym Inc. (“Enedym”), a technology company that develops next generation switched reluctance motors (SRMs), electric propulsion, and electrified powertrains, today announced a strategic partnership with Smartricity Inc. (“Smartricity”), a smart industrial electric motor and software company. The partnership will help deliver next generation wind pitch motors and related technology to materially increase efficiency, performance, and cost-effectiveness.
Utilizing Enedym’s unique SRM technology, Ventium – whose name is a combination of the Latin words for wind (Ventus) and power (Imperium) – increases the reliability and efficiency of wind turbines, which leads to an increase in energy production. Over time, increased wind energy production will displace fossil fuel electricity generation, resulting in significant reductions in greenhouse gas emissions. In addition, increased efficiency of wind turbines reduces the cost of wind energy, making investments in clean wind energy more attractive. Enedym and consortium partner Smartricity, were recently awarded $2.4 million by Sustainable Development Technology Canada (SDTC) to commercialize and advance the Ventium wind pitch motor technology.
As part of the collaboration, Enedym and Smartricity will work to maximize the contribution that wind energy can make by addressing a major weakness in turbines: low availability and capacity factor due to unreliable and outdated wind pitch drive systems in 1.X-2.X MW models. The pitch systems in the 1.X-2.X are one of the largest contributors to turbine downtime, with studies showing over 30% of failures directly related to these systems.
Dr. Ali Emadi, Founder, President, and CEO of Enedym said, “We are pleased to announce this agreement with Smartricity and jointly reach our goal to ensure wind power infrastructure can run more efficiently, reliably, and economically. Global appetite for clean energy is projected to accelerate dramatically, both to reduce reliance on foreign fossil fuel-based power generation and to ensure geo-political risks are reduced. We are eager to partner and work with Smartricity, industry leaders, and renewable energy companies to drive the innovation that will move us towards a greener and more secure future.”
Michael Sonsogno, Co-Founder and CEO of Smartricity, said, “Smartricity has built an arsenal of revolutionary motor technologies from around the world and paired it with our team’s expert application knowledge to address major weaknesses in the Renewables, HVAC, Mining, Oil and Gas, and Industrial Manufacturing industries. In the Wind Pitch application, SRM was the clear winner when combined with our real-world field insights to produce the Ventium Wind Pitch SRM.”
About Enedym Inc.
Enedym is a technology start-up company from McMaster University. The company is headquartered at the McMaster Innovation Park in Hamilton, Ontario, Canada. Enedym has ownership of over 60 patents and pending patent applications and related inventions developed by the Canada Excellence Research Chair in Hybrid Powertrain Dr. Ali Emadi and his research group at the McMaster Automotive Resource Centre (MARC), McMaster University. Enedym’s vision is to significantly reduce the cost of electric motors and electrified powertrains, and power a new paradigm in electrification through novel electric motor drive technologies, controls, and digitization techniques. Enedym aspires to help save the planet, one electric motor market at a time. To learn more about Enedym, please visit www.enedym.com and our YouTube channel at Enedym YouTube .
About Smartricity Inc.
Smartricity is a smart industrial electric motor and software company. Smartricity’s motors are created using disruptive electric motor technologies, software, and data analytics; Smartricity’s highly efficient, ultra-reliable, and sustainable motors will drastically increase critical asset uptime while greatly reducing emissions, waste, and massive industrial carbon footprint. To learn more about Smartricity and the Ventium Wind Pitch SRM please visit www.Smartricity.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005647/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom